MRI-PDFF: Liver Fat
MRI-PDFF (proton density fat fraction) measures how much fat is in the liver. It is the most accurate noninvasive method for measuring liver fat, with high agreement with biopsy findings.
AI Summary The MAST score combines an MRI-PDFF liver fat measurement, an MRE liver stiffness measurement, and an AST blood test into one number. It estimates the chance of significant fibrosis or MASH without a biopsy. Below 0.165 is low risk, 0.165 to 0.242 is intermediate, and above 0.242 is high. The score is an estimate, not a diagnosis, so your doctor reads it with your other results and may suggest follow-up or a specialist visit.
Source: www.liverdirectory.com
Medically Reviewed.
The MAST score, short for MRI-AST, is a non-invasive score for people with fatty liver disease. It combines two MRI measurements with one blood test result to estimate how likely you are to have significant liver scarring (fibrosis) or metabolic dysfunction–associated steatohepatitis (MASH).
It does not need a needle in your liver. Your care team reads the score alongside your health history and other tests, and uses it to decide whether you need closer monitoring or a visit with a liver specialist.
Ask Aimy
Aimy answers from LiverDirectory’s reviewed health information — helping patients make sense of liver-health terms, prepare for specialist visits, and explore what to look up next.
NONINVASIVE FATTY LIVER SCORE
The MAST score (MRI-AST score) estimates two things in a person with fatty liver disease: how much fibrosis (scar tissue) the liver has, and how likely it is that the liver has MASH. MASH, formerly called NASH, is a more severe form of fatty liver. If it goes untreated, it can lead to fibrosis, cirrhosis, or liver failure.
The MAST score is not a single scan. It is a calculation. It uses an MRI to measure liver fat and liver stiffness, and a blood test for a liver enzyme called AST. The three results combine into one number.
The score gives your doctor a detailed look at liver health without a biopsy. A liver biopsy removes a small piece of liver tissue. The MAST score does not.
The MAST score is one of several MAFLD / MASH scores. Each uses different inputs to estimate the same kind of risk.
MRI AND BLOOD TEST INPUTS
The score takes three results and turns them into one number. Two come from the same MRI visit. One comes from a blood draw.
MRI-PDFF (proton density fat fraction) measures how much fat is in the liver. It is the most accurate noninvasive method for measuring liver fat, with high agreement with biopsy findings.
MRE (magnetic resonance elastography) measures liver stiffness. Scar tissue makes the liver firmer, so stiffness is a stand-in for fibrosis. MRE creates a visual map of stiffness across the liver.
AST (aspartate aminotransferase) is a liver enzyme that rises with liver injury. It comes from a standard blood draw, often part of routine liver blood work.
WHEN DOCTORS ORDER IT
Doctors use the MAST score when they need a closer look at fatty liver disease and want to avoid a biopsy.
Obesity, diabetes, and high cholesterol raise the risk of fatty liver disease. If you have these, your doctor may use the score to check for scarring or early MASH.
The score estimates the chance of significant fibrosis or MASH. Finding either early gives you time to act before scarring advances.
A repeat score can show whether your liver is changing after lifestyle or medical changes.
A biopsy carries risks, including pain and bleeding, and the sample can miss the problem area. Noninvasive tests are safer and repeatable. Sequential testing, such as a blood test followed by imaging, also helps reduce unnecessary biopsies.
MRI AND BLOOD DRAW VISIT
There is no separate MAST test. You have an MRI visit and a blood draw, and your care team calculates the score from the results.
Your clinic will tell you how to prepare, including whether to fast before the scan. Tell the imaging team about any allergies, metal implants, or discomfort in small spaces before the exam.
LOW, MID, AND HIGH RISK
Your score falls into one of three risk groups. The groups show how likely it is that you have significant fibrosis or MASH. They are not a diagnosis.
Combines MRI-PDFF, MRE, and AST into one risk estimate.
0.165 to 0.242 (intermediate risk)
Below 0.165 is low risk. Little or no fibrosis or MASH is likely. Your doctor may advise a healthy lifestyle and routine monitoring.
0.165 to 0.242 is intermediate risk. Some fibrosis or fat buildup may be present. Your doctor may advise more monitoring, more imaging, or lifestyle changes.
Above 0.242 is high risk. Significant fibrosis or MASH is likely. Your doctor will likely advise a specialist evaluation and may discuss treatment.
A high score does not confirm MASH, and a low score does not rule out every problem. A biopsy may still be used when noninvasive results are unclear or before some treatments.
ACCURACY AND TEST LIMITATIONS
Histology, the study of a liver tissue sample, remains the gold standard for diagnosing MASH. The MAST score helps your doctor decide who needs that step.
Noninvasive tests are more accurate for finding cirrhosis than for telling apart the middle stages of fibrosis. An intermediate score is therefore a reason for follow-up, not a firm answer.
AST rises with liver injury. Other liver problems can raise it too, so your doctor considers your full history when reading the score.
FIBROSIS AND MASH TEST OPTIONS
Several non-invasive options estimate the same kind of risk. Your care team chooses based on your situation and what testing is available.
| Test | What it uses | What it estimates |
|---|---|---|
| MAST score | MRI-PDFF, MRE, and AST blood test | Likelihood of significant fibrosis or MASH |
| FAST score | FibroScan stiffness, FibroScan fat measure (CAP), and AST | Likelihood of MASH with significant fibrosis |
| cTAG score | MRI marker cT1, AST, and blood glucose | Risk of significant fibrosis |
| Liver biopsy | A small sample of liver tissue | Fibrosis and MASH, confirmed under a microscope |
Learn more about the [FAST score](/liver-tests/medical-scores/mafld-mash-scores/fast-score) and the [SAFE score](/liver-tests/medical-scores/mafld-mash-scores/safe-score).
FOLLOW-UP AFTER YOUR SCORE
Ask your doctor to explain your score and which risk group you fall into. Ask what the result means for your follow-up schedule. Bring a list of your medicines and any earlier liver test results.
Lifestyle change is the cornerstone of care for fatty liver disease. Helpful steps include regular physical activity, gradual weight loss of 5 to 10 percent if you are overweight, a diet rich in vegetables, fruits, whole grains, lean protein, and healthy fats, and limiting alcohol. Early fatty liver can often be reversed with these steps.
A high score, or a score your doctor finds unclear, often leads to a visit with a liver specialist. Some adults with MASH and moderate to advanced fibrosis may be considered for medicine such as [resmetirom](/liver-therapies/metabolic-masld-mash-therapies/thr-beta-agonist-therapy/resmetirom). Your specialist decides what fits you. Learn more about [metabolic therapies](/liver-therapies/metabolic-masld-mash-therapies/additional-metabolic-therapies).
AFTER YOUR SCORE
Your score helps your doctor decide on next steps. Read about therapies for fatty liver disease and MASH.
A balanced, liver-friendly diet supports your liver, helps manage weight and blood sugar, and lowers the risk of other health problems during long-term follow-up.
Explore Liver DietThe Amsety Bar is a liver-friendly snack or meal replacement that can make it easier to eat well on busy days.
Shop Amsety Bars
Common Questions
A MAST score is a number that estimates how likely you are to have significant liver fibrosis or MASH. MAST stands for MRI-AST. It is a calculation, not a single scan. It combines liver fat (MRI-PDFF), liver stiffness (MRE), and an AST blood test. AST is a liver enzyme that rises with liver injury. The score is a risk estimate, not a diagnosis. Your doctor reads it with your health history and your other test results.
No. The MAST score comes from an MRI and a blood test, so no tissue sample is taken. A liver biopsy removes a small piece of liver tissue. A biopsy carries risks, including pain and bleeding, and the sample can miss the problem area. Your doctor may still suggest a biopsy if your results are unclear or if you need confirmation before some treatments.
A score above 0.242 is high risk. It means significant fibrosis (scar tissue) or MASH is likely. It does not confirm a diagnosis. Histology, the study of a liver tissue sample, remains the gold standard for diagnosing MASH. Your doctor will likely advise a specialist evaluation and may discuss next steps, including treatment. Ask your doctor what the result means for your follow-up schedule.
A score below 0.165 is low risk. It points to little or no fibrosis or MASH. A low score does not rule out every problem, so your doctor still considers your full history. Your doctor may advise a healthy lifestyle and routine monitoring. Keep up with any follow-up visits, even when your result is reassuring.
Scores from 0.165 to 0.242 are intermediate risk. Some fibrosis or fat buildup may be present. This range is a reason for follow-up, not a firm answer. Noninvasive tests are more accurate for finding cirrhosis than for telling apart the middle stages of fibrosis. Your doctor may suggest more monitoring, more imaging, or lifestyle changes.
Medical disclaimer: LiverDirectory provides educational information and a directory of providers. It does not provide medical advice, diagnosis, or treatment. Always consult a licensed physician regarding any medical condition.